Omniome developed a proprietary short-read DNA sequencing platform based on Sequencing by Binding (SBB) chemistry. Acquired by PacBio in September 2021 for ~$800 million.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2021
Jan 2020
Jul 2018
Create a free account to see which investors have funded this company.
Create Free AccountBiopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Life science company democratizing access to advanced DNA sequencing tools with high-quality, aff...
Novel DNA sequencing architecture to scale the ultra low cost whole genome
